• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

The mRNA COVID-19 vaccine in patients with cancer receiving checkpoint inhibitor therapy: what we know and what we don't.

作者信息

Malek Alexandre E, Cornejo Paulette Pinargote, Daoud Nour, Alam Mohammad

机构信息

Department of Medicine, Division of Infectious Diseases, Louisiana State University Health Sciences Center, Shreveport, LA 71103, USA.

出版信息

Immunotherapy. 2022 Feb;14(2):91-94. doi: 10.2217/imt-2021-0235. Epub 2021 Nov 8.

DOI:10.2217/imt-2021-0235
PMID:34747190
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC8582594/
Abstract
摘要

相似文献

1
The mRNA COVID-19 vaccine in patients with cancer receiving checkpoint inhibitor therapy: what we know and what we don't.接受检查点抑制剂治疗的癌症患者接种新冠病毒mRNA疫苗：我们已知与未知的情况
Immunotherapy. 2022 Feb;14(2):91-94. doi: 10.2217/imt-2021-0235. Epub 2021 Nov 8.
2
Indications for and contraindications of immune checkpoint inhibitors in cancer patients with COVID-19 vaccination.癌症合并 COVID-19 疫苗接种患者免疫检查点抑制剂的适应证和禁忌证。
Future Oncol. 2021 Sep;17(26):3477-3484. doi: 10.2217/fon-2021-0288. Epub 2021 Jun 30.
3
mRNA COVID-19 vaccines in patients with chronic lymphocytic leukemia: A systematic review and meta-analysis.慢性淋巴细胞白血病患者接种新型冠状病毒 mRNA 疫苗：一项系统评价与荟萃分析。
Eur J Haematol. 2022 Mar;108(3):264-267. doi: 10.1111/ejh.13729. Epub 2021 Dec 13.
4
What is the immunological response to BNT162b2 mRNA vaccine in immunocompromised patients?免疫功能低下患者对BNT162b2 mRNA疫苗的免疫反应是什么？
EBioMedicine. 2021 Dec;74:103733. doi: 10.1016/j.ebiom.2021.103733. Epub 2021 Dec 1.
5
COVID-19 Vaccination Imperatives in People on Maintenance Dialysis: An International Perspective.维持性透析患者的 COVID-19 疫苗接种必要性：国际视角
Clin J Am Soc Nephrol. 2021 Nov;16(11):1746-1748. doi: 10.2215/CJN.07260521. Epub 2021 Jul 19.
6
Three, four or more: what's the magic number for booster shots?三剂、四剂还是更多剂：加强针的神奇数字是多少？
Nature. 2022 Feb;602(7895):17-18. doi: 10.1038/d41586-022-00200-9.
7
Short-term safety of the BNT162b2 mRNA COVID-19 vaccine in patients with cancer treated with immune checkpoint inhibitors.BNT162b2 mRNA新冠疫苗在接受免疫检查点抑制剂治疗的癌症患者中的短期安全性
Lancet Oncol. 2021 May;22(5):581-583. doi: 10.1016/S1470-2045(21)00155-8. Epub 2021 Apr 1.
8
Vaccines to prevent COVID-19: A living systematic review with Trial Sequential Analysis and network meta-analysis of randomized clinical trials.预防 COVID-19 的疫苗：一项针对随机临床试验的实时系统评价与序贯分析和网络荟萃分析。
PLoS One. 2022 Jan 21;17(1):e0260733. doi: 10.1371/journal.pone.0260733. eCollection 2022.
9
The Century of mRNA Vaccines: COVID-19 Vaccines and Allergy.mRNA疫苗的世纪：新冠疫苗与过敏
J Investig Allergol Clin Immunol. 2021 Feb 17;31(1):89-91. doi: 10.18176/jiaci.0665. Epub 2020 Jan 4.
10
Overlap of immunotherapy-related pneumonitis and COVID-19 pneumonia: diagnostic and vaccine considerations.免疫治疗相关肺炎与 COVID-19 肺炎的重叠：诊断和疫苗接种的考虑因素。
J Immunother Cancer. 2021 Apr;9(4). doi: 10.1136/jitc-2020-002307.

引用本文的文献

1
Periodic Boosters of COVID-19 Vaccines Do Not Affect the Safety and Efficacy of Immune Checkpoint Inhibitors for Advanced Non-Small Cell Lung Cancer: A Longitudinal Analysis of the Vax-On-Third Study.新冠疫苗的定期加强针不影响晚期非小细胞肺癌免疫检查点抑制剂的安全性和疗效：Vax-On-Third研究的纵向分析
Cancers (Basel). 2025 Jun 11;17(12):1948. doi: 10.3390/cancers17121948.
2
COVALENCE STUDY: Immunogenicity and Reactogenicity of a COVID-19 mRNA Vaccine in an Open-Label Cohort of Long-Survivor Patients with Metastatic Lung Cancer.共价研究：新冠病毒mRNA疫苗在转移性肺癌长期存活患者开放标签队列中的免疫原性和反应原性
Vaccines (Basel). 2025 Mar 5;13(3):273. doi: 10.3390/vaccines13030273.
3
Immune-related adverse events and disease outcomes after the third dose of SARS-CoV-2 mRNA-BNT162b2 vaccine in cancer patients receiving immune checkpoint inhibitors.免疫检查点抑制剂治疗的癌症患者接种第三剂 SARS-CoV-2 mRNA-BNT162b2 疫苗后的免疫相关不良事件和疾病结局。
Cancer Immunol Immunother. 2023 Oct;72(10):3217-3228. doi: 10.1007/s00262-023-03489-1. Epub 2023 Jul 10.
4
Immune responses to SARS-CoV-2 in vaccinated patients receiving checkpoint blockade immunotherapy for cancer.接种疫苗的癌症患者在接受免疫检查点阻断免疫疗法时对 SARS-CoV-2 的免疫反应。
Front Immunol. 2022 Dec 13;13:1022732. doi: 10.3389/fimmu.2022.1022732. eCollection 2022.
5
Cancer Patients and the COVID-19 Vaccines: Considerations and Challenges.癌症患者与新冠疫苗：考量与挑战
Cancers (Basel). 2022 Nov 16;14(22):5630. doi: 10.3390/cancers14225630.
6
Diabetic ketoacidosis shortly after COVID-19 vaccination in a non-small-cell lung cancer patient receiving combination of PD-1 and CTLA-4 inhibitors: A case report.一名接受PD-1和CTLA-4抑制剂联合治疗的非小细胞肺癌患者在接种新冠疫苗后不久发生糖尿病酮症酸中毒：病例报告
Thorac Cancer. 2022 Apr;13(8):1220-1223. doi: 10.1111/1759-7714.14352. Epub 2022 Feb 14.

本文引用的文献

1
The NCCN 2021 Virtual Congress: Hematologic Malignancies.2021年美国国立综合癌症网络（NCCN）虚拟大会：血液系统恶性肿瘤
J Natl Compr Canc Netw. 2021 Nov 1;19(11.5):1323. doi: 10.6004/jnccn.2021.5100.
2
Immune responses to two and three doses of the BNT162b2 mRNA vaccine in adults with solid tumors.成年人实体瘤中接受两剂和三剂 BNT162b2 mRNA 疫苗的免疫反应。
Nat Med. 2021 Nov;27(11):2002-2011. doi: 10.1038/s41591-021-01542-z. Epub 2021 Sep 30.
3
Effect of Immunosuppression on the Immunogenicity of mRNA Vaccines to SARS-CoV-2 : A Prospective Cohort Study.免疫抑制对SARS-CoV-2 mRNA疫苗免疫原性的影响：一项前瞻性队列研究。
Ann Intern Med. 2021 Nov;174(11):1572-1585. doi: 10.7326/M21-1757. Epub 2021 Aug 31.
4
Immune checkpoint inhibitors increase T cell immunity during SARS-CoV-2 infection.免疫检查点抑制剂可增强 SARS-CoV-2 感染期间的 T 细胞免疫。
Sci Adv. 2021 Aug 18;7(34). doi: 10.1126/sciadv.abg4081. Print 2021 Aug.
5
COVID-19 mRNA vaccines and immune-related adverse events in cancer patients treated with immune checkpoint inhibitors.新型冠状病毒肺炎信使核糖核酸疫苗与接受免疫检查点抑制剂治疗的癌症患者的免疫相关不良事件
Eur J Cancer. 2021 Sep;155:291-293. doi: 10.1016/j.ejca.2021.07.017. Epub 2021 Jul 28.
6
Durability of Response to SARS-CoV-2 BNT162b2 Vaccination in Patients on Active Anticancer Treatment.接受活性抗肿瘤治疗患者对 SARS-CoV-2 BNT162b2 疫苗接种的反应持久性。
JAMA Oncol. 2021 Nov 1;7(11):1716-1718. doi: 10.1001/jamaoncol.2021.4390.
7
Immunogenicity of the BNT162b2 COVID-19 mRNA vaccine and early clinical outcomes in patients with haematological malignancies in Lithuania: a national prospective cohort study.立陶宛血液系统恶性肿瘤患者的 BNT162b2 COVID-19 mRNA 疫苗免疫原性和早期临床结局：一项全国前瞻性队列研究。
Lancet Haematol. 2021 Aug;8(8):e583-e592. doi: 10.1016/S2352-3026(21)00169-1. Epub 2021 Jul 2.
8
Three Doses of an mRNA Covid-19 Vaccine in Solid-Organ Transplant Recipients.实体器官移植受者接种三剂mRNA新冠疫苗
N Engl J Med. 2021 Aug 12;385(7):661-662. doi: 10.1056/NEJMc2108861. Epub 2021 Jun 23.
9
Evaluation of Seropositivity Following BNT162b2 Messenger RNA Vaccination for SARS-CoV-2 in Patients Undergoing Treatment for Cancer.评估接受癌症治疗的患者接种 BNT162b2 信使 RNA 疫苗后针对 SARS-CoV-2 的血清阳性率。
JAMA Oncol. 2021 Aug 1;7(8):1133-1140. doi: 10.1001/jamaoncol.2021.2155.
10
COVID-19 Vaccines in Patients With Cancer-A Welcome Addition, but There Is Need for Optimization.癌症患者的新冠疫苗——一项受欢迎的补充，但仍需优化。
JAMA Oncol. 2021 Aug 1;7(8):1113-1114. doi: 10.1001/jamaoncol.2021.1218.